INTRODUCTION
Gram-negative sepsis, a relatively rare clinical diagnosis only a few decades ago, is perhaps the most important infectious disease problem in hospitals today. Despite recent advances in our understanding of the pathophysiological mechanisms of sepsis and improved antimicrobial therapy, the mortality rate from gram-negative sepsis remains frustratingly high, particularly after the onset of shock.
Unfortunately, many of the therapeutic methods proposed over the years for the management of sepsis and its complications have either failed to meet their initial expectations or remain unproved, despite many anecdotal reports. Recently, however, the development of new monoclonal antibodybased treatments, together with earlier recognition of and intervention in the pathogenetic process, has raised the hope that a significant reduction in deaths from gram-negative sepsis can be achieved.
This article reviews the epidemiology, diagnosis, and current management of gram-negative sepsis and examines the therapeutic potentials of new treatment modalities being developed.
DEFINITIONS
The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (12) was the latest in a series of ongoing attempts (7) (8) (9) (10) to provide a conceptual and practical framework in which to define the systemic inflammatory response to infection that often underlies sepsis. The term sepsis has traditionally been used to describe this progressive process, which is also associated with organ damage. Acceptance of the broad definitions proposed at the consensus conference would make early detection and treatment of disease possible and would facilitate the standardization of research protocols. The interpretation of clinical trials designed to evaluate conventional and innovative therapies for sepsis can be expected to improve if the use of disparate definitions for such terms as infection, bacteremia, sepsis, septicemia, sepsis syndrome, and septic shock can be avoided. The new terms and definitions proposed by the conference can be found in Table 1 .
INCIDENCE AND NATURAL HISTORY
Sepsis is not a reportable disease, and it is possible that many deaths due to sepsis are attributed to underlying diseases when mortality statistics are compiled (86) . Published estimates of up to 300,000 cases of sepsis per year in the United States may be realistic (47, 86) . Estimated mortality from sepsis of gram-negative etiology ranges from 20 to 50% of the overall total number of septic deaths (75, 86) ; the fraction is notably higher among the approximately 40% of septic patients who develop shock. Among patients who develop the complications of shock and organ failure, mortality can reach 90% (9) . Sepsis therefore represents a leading cause of death in the United States, and its incidence has increased significantly over the past decade (20) .
A significant proportion of sepsis cases are caused by gram-negative bacilli (19) . Table 2 shows the distribution of gram-negative isolates and their associated mortality rates, as summarized by Young from 11 studies reported from 1955 to 1986 (86) . In that review, Escherichia coli was the most commonly isolated pathogen, followed by Klebsiella and Enterobacter species (86) . Although Pseudomonas species were encountered somewhat less frequently, Pseudomonas aenrginosa has consistently been associated with the highest mortality rate among all causes of bacteremic infection (86) . In the studies listed in Table 2 , the mortality rates associated with gram-negative sepsis were as high as 61% and exceeded 25% in all but three of the centers involved.
From 1987 to 1988, a number of centers participated in a prospective national study of the natural history of gramnegative sepsis (49) . A total of 226 patients with presumed gram-negative sepsis were available for analysis. Gramnegative bacteria were isolated from 152 patients (67%). At day 14, mortality was 26% for those patients with documented gram-negative sepsis and 23% for those from whom no gram-negative organism was isolated. The presence of the adult respiratory distress syndrome or disseminated intravascular coagulation during the first week of illness was the variable most predictive of death. (48) . Nearly 80% of all documented epidemics were caused by gram-negative bacilli.
RISK FACTORS
Although the survival of patients with progressive or chronic illnesses has been prolonged by better treatments for the primary disease, debilitation eventually occurs, and these patients become the immunocompromised targets of systemic infection.
DIAGNOSIS
In recent studies on the efficacy of methylprednisolone treatment for septic patients (13, 14) , the inclusion criteria for study subjects included the following: a presumed site of infection, hyper-or hypothermia, tachycardia, tachypnea, and inadequate organ perfusion or function. Manifestations of insufficient perfusion included altered mental state, hypoxemia, elevated levels of plasma lactate, and oliguria. Bacteremia and hypotension were not essential for the diagnosis of sepsis syndrome in those studies.
Fever, the most common sign of sepsis, is believed to be caused by the actions of a number of endogenous substances on prostaglandin E2 synthesis (3, 25, 26, 37) . Hypothermia is seen principally in older patients (33, 37) . Cardiac manifestations of sepsis range from tachycardia and increased cardiac output to myocardial failure (37) . Respiratory signs of sepsis include respiratory alkalosis, hyperventilation, failure of respiratory muscles, and the adult respiratory distress syndrome, considered a catastrophic complication (6, 42, 54, 86) .
An increase in cardiac output is often seen early in the course of the systemic inflammatory response syndrome (SIRS) but is usually offset by decreased peripheral resistance in the preshock state (37) . Early shock is accompanied by a significant decline in systemic vascular resistance that may precede the fall in blood pressure (37) . In later shock, declining cardiac output, vasoconstriction, and refractory hypotension may occur; alternatively, vasodilation may persist even in late shock (37, 86) .
Renal manifestations of SIRS include azotemia and oliguria that result from renal tubular injury (37) . Liver dysfunction may be revealed by a rise in serum bilirubin levels that frequently precedes the clinical signs of infection (29) . Hematological abnormalities associated with SIRS include eosinopenia (37), vacuolization of neutrophils (91) , reduced levels of iron in the serum (41) , and the disseminated intravascular coagulation syndrome (37) . Thrombocytopenia is often noted at an early stage of SIRS (58) , as is hyperglycemia in diabetic patients (36, 37) . A variety of changes in mental status is possible in the septic patient, including disorientation, lethargy, confusion, agitation, and obtundation (37, 86 (15, 56) . In his experiments, Pfeiffer noted that lysates of heat-inactivated Vibrio cholerae caused shock and death in laboratory animals. He called the toxic substance, not yet characterized, "endotoxin" on the assumption that it was found inside the bacterium. This also served to distinguish it from toxins secreted during bacterial growth in culture (51, 56) .
In the 1930s, endotoxins were isolated and characterized as lipopolysaccharide (LPS)-phospholipid-protein complexes present in the bacterial outer membrane (8, 51) . Subsequent efforts yielded purified and protein-free LPS that could produce all of the physiological effects of the impure substance isolated earlier (51, 78) . Later experiments suggested that a chemical subunit of LPS, lipid A, was the actually toxic moiety (51, 77) and that the 0-specific chain found on LPS was not involved in the toxic effect (15, 31) .
The structure of the LPS molecule is shown schematically in Fig. 1 (27, 59 (27, 30) . On the other hand, lipid A is the most highly conserved subunit of the gram-negative LPS structure (51) . Chemically, the toxic lipid A moiety has been characterized as an esterlinked glucosamine with both ester-and amide-linked pyrophosphates and fatty acids (17, 51) . The form of lipid A produced by E. coli has now been synthesized in the laboratory (15, 39) . The physiological effects of endotoxin in vivo and the biochemical mechanisms underlying these effects have been extensively investigated. The administration of small doses of endotoxin to animals affects their hemodynamics, body temperature, blood clotting, cellular and humoral immunities, and other important physiologic parameters; large doses are lethal (16) . In most species, the injection of LPS is associated with a rapid onset of fever, hypotension, and neutropenia (16 (68) . Three hours after dosing, systemic vascular resistance and mean arterial pressure had decreased by 46 and 18%, respectively, while the cardiac index had increased by 53% and the heart rate had increased by 36%. Left ventricular function, both before and after volume loading, was consistent with the hemodynamic alterations observed in septic shock.
The profound effects of endotoxin on clotting are demonstrated by both local and generalized Schwartzman reactions (65) . In animal studies, these reactions have been incited by two injections of endotoxin 12 to 18 h apart. In the local reaction, an intradermal injection followed by an intravenous injection produces hemorrhagic necrosis at the extradermal injection site. In the generalized reaction, sequential intravenous injections produce bilateral renal cortical necrosis in the test animals. This occurs as a result of the occlusion of small vessels by fibrin and intravascular coagulation (16) .
Endotoxin can also affect the blood cells, inducing neutropenia, leukocytosis, and a reduction in circulating platelets (16) . The proliferation of B lymphocytes and macrophages is also stimulated by endotoxin.
It is generally agreed that most of the adverse effects associated with endotoxin result from its capacity to cause the release of various endogenous mediators and to act on a number of important biochemical pathways, as shown in Fig. 2 (53) . The cytokines are an important group of mediators whose release occurs in sepsis. These include tumor necrosis factor and interleukin-1, both released by macrophages (86) . Tumor necrosis factor is believed to be a primary mediator of the events that occur in sepsis, since the direct infusion of a recombinant form of this mediator produces most of the adverse effects seen after endotoxin administration (69) .
Tumor necrosis factor and interleukin-1 are both endogenous pyrogens that contribute to the febrile response seen in sepsis (27, 86) . Tumor necrosis factor may also act synergistically with interleukin-1, gamma interferon, or both to trigger a systemic inflammatory response and cause damage to the vascular endothelium (86) . Tumor necrosis factor may also provoke the release of prostaglandins (86) and other lipid mediators of shock, including platelet-activating factor, leukotrienes C4 and D4, and thromboxane A, (44) . The adverse effects of these lipid mediators include increased vascular permeability and vasoactivity and the contraction of pulmonary smooth muscle (16, 44) .
Another key action of endotoxin is its effect on the coagulation system. Endotoxin activates factor XII (Hageman factor), which in turn initiates the intrinsic clotting sequence that eventually results in the conversion of fibrinogen (factor 1) to fibrin (86 Hageman factor by endotoxin is also an initial step in complement and kinin system activation. Complement activation by endotoxin can take place by way of both the classic and the alternative pathways (16, 86) . Although the complement system is important in the lysis and phagocytosis of pathogenic organisms, overstimulation of the system can have deleterious effects. One such event is the increased chemotaxis of polymorphonuclear leukocytes caused by complement activation, which can produce pulmonary leukostasis, an important factor in the development of the adult respiratory distress syndrome (63) .
After its activation by endotoxin, Hageman factor also stimulates the conversion of prekallikrein to kallikrein and the subsequent conversion of kininogen to bradykinin (86) . Bradykinin can have a number of adverse effects on the vascular system, including an increase in vascular permeability and a decrease in vascular resistance that can lead to hypotension (52, 86) .
Other endogenous vasoactive substances that are probably affected by endotoxin are catecholamines, endorphins, the neurotransmitter serotonin, and adrenal corticoids (86) .
The mechanisms by which these mediators are released and the clinical significance of their release are subjects for further investigation.
Antibodies of the immunoglobin G (IgG) and IgM classes that are directed against 0 and K polysaccharide antigens have opsonic and bactericidal activities, especially in the presence of complement (86) . Other antibodies directed against the core regions of the gram-negative bacterial cell wall appear to neutralize endotoxin (86) . These observations provide the rationale for efforts to develop an anti-endotoxin antiserum with broad reactivity against the cell walls of important gram-negative pathogens. Advances along this line of research along with the effective use of hybridoma technology have produced new agents with exciting potential to fight sepsis. Some of these agents are being tested and should soon be commercially available. These developments are discussed in greater detail in the final section of this review.
MANAGEMENT
The early administration of appropriate antimicrobial therapy is an important aspect of the effective management of sepsis (70, 86) . In one large study, treatment with appropriate antibiotics reduced shock and mortality rates by 50% (43) . Because the results of blood culture and susceptibility testing cannot usually be provided in less than 48 to 72 h and because more than 50% of the deaths caused by gramnegative sepsis occur during the first 2 days of the illness, empirical, parenteral, broad-spectrum antibacterial therapy is a widely accepted treatment mode (43, 70, 86 tobramycin in the blood should be maintained at between 6 and 10 ,g/dl, while trough levels should fall below 2 ,ug/dl to decrease the chances of ototoxicity or nephrotoxicity (62) . Frequent monitoring of drug levels in the blood is therefore required.
For hospital-acquired infections in non-neutropenic patients, an expanded-spectrum cephalosporin rather than an aminoglycoside is often used because the etiologic organism is more likely to be a Kiebsiella sp. than a Pseudomonas sp. In patients with presumed P. aeruginosa infection, including those with neutropenia, burns, or infection related to respiratory therapy, an antipseudomonal penicillin such as mezlocillin, piperacillin, ticarcillin, or azlocillin may be substituted for the cephalosporin and used in combination with an aminoglycoside (85) . In the case of resistance to both cephalosporins and penicillins, imipenem may be used with the aminoglycoside (86) .
The rationale for using a combination of two antibiotics is based on several considerations, including the broad coverage of potential pathogens, the frequency of polymicrobial infections, and the possibility of antibacterial synergy between the two agents. Such synergistic combinations have been associated with improved clinical results (2) . In addition, such combinations may reduce the chances of emergent resistance by eliminating secondary bacterial populations that are resistant to one drug but not both (86 ance is an important supportive measure in the treatment of sepsis, particularly when shock ensues. Sympathomimetic amines may also be administered to manage the hemodynamic complications encountered in septic shock. Table 3 summarizes the recommended sympathomimetic amines for use to control shock. Dopamine raises the heart rate and systolic blood pressure at higher infusion rates. Many clinicians prefer to use low-dose dopamine (1 to 10 ,ug/kg of body weight per min) for its effect on renal perfusion (dopaminergic effect). Dobutamine may be added to the therapeutic regimen to increase myocardial contractility. If systolic blood pressure is still not adequate, norepinephrine is titrated to increase blood pressure through an increase in systemic vascular resistance. Compared with dopamine, dobutamine has less influence on heart rate and causes a decrease in pulmonary capillary wedge pressure. Isoproterenol does not markedly elevate blood pressure, but it does increase the cardiac index (79) . Adequate volume replacement must be achieved before any sympathomimetic amine is administered (86) .
Despite extensive investigation, the utility of a number of drugs in the treatment of septic shock remains controversial. Disagreement concerning the use of glucocorticoids has persisted for many years. The finding that corticosteroid treatment improved survival in laboratory animal models of sepsis was supported by the results of a 1976 clinical trial (64) . Although this study was prospective and randomized, concerns were raised regarding certain aspects of the trial design. Sprung et al. compared the effect of a two-dose steroid regimen with that of placebo in patients with septic shock and found no significant between-treatment differences in mortality rates (66) . In 1987, two large, controlled trials of glucocorticoid therapy in sepsis were published simultaneously, one by The Veterans Administration Systemic Sepsis Cooperative Study Group (72) and the other by the Methylprednisolone Severe Sepsis Study Group (13) . Both trials were prospective, randomized comparisons of high-dose methylprednisolone sodium succinate and placebo. In the Veterans Administration study, 14-day mortality was similar in the glucocorticoid (21%) and placebo (22%) groups. The resolution of secondary infection was significantly higher in patients who received placebo (P = 0.03).
In the second study of methylprednisolone, mortality at 14 days was not improved by steroids, nor were treatmentrelated differences in the reversal of shock observed. The authors of both of these important studies concluded that high-dose glucocorticoid therapy provides no benefit in patients with sepsis and septic shock and should not be used. It is now widely accepted that glucocorticoids should not be used in the treatment of septic shock (57) .
The opiate antagonist naloxone has attracted interest because of its capacity to alter endotoxic shock in animals (28) . In a small trial published in 1981, Peters et al. observed a 45% increase in systolic blood pressure after the administration of 0.4 to 1.2 mg of naloxone to eight patients with sepsis who were not receiving corticosteroids (55) . Increased blood pressure was evident within a few minutes of the intravenous injection and lasted for about 45 min. Four years later, however, DeMaria and associates performed a double-blind, placebo-controlled study of intravenous bolus naloxone in septic shock patients and found no significant between-treatment differences in either blood pressure elevation or survival (24) . In the most recent study of naloxone in the treatment of sepsis, Roberts et al. gave either placebo or a 30-pg/kg intravenous bolus injection plus an additional 30-p,g/kg infusion of naloxone to 14 patients with septic shock who required the support of inotropes, vasopressors, or both (61) . The infusions of naloxone or placebo were administered over a period of 16 to 18 h. Pulmonary wedge pressure and pH were kept constant, and inotrope or vasopressor therapy was titrated to maintain a fixed mean blood pressure. Inotrope or vasopressor requirements were significantly lower in the naloxone-treated group than in the placebo group at 8 (P < 0.005) and 16 (P < 0.02) h. Significant improvements were also seen in stroke volume and heart rate in the group that received naloxone compared with those who received placebo. Because the positive hemodynamic effects seen in the naloxone group were observed only after 4 h, earlier studies utilizing bolus injections may not have provided an optimal drug regimen and observation period. Additional studies with naloxone are needed to clarify its role in the management of septic shock.
Anticoagulants, particularly heparin, have been widely used in the management of disseminated intravascular coagulation. Although these agents can ameliorate the clinical expressions of coagulopathy (23), they have not been shown to reduce mortality, and their use is probably best reserved for other indications (86) .
Transfusions of granulocytes for both the prophylaxis and treatment of sepsis have been studied. In trials involving prophylactic transfusions, investigators augmented the circulating granulocyte pool in patients scheduled to undergo aggressive chemotherapy for bone marrow transplantation or leukemia (22, 67, 81) . The results of these studies suggested that any modest reductions in the incidence of gramnegative infection due to the infusions were countered by an increased incidence of pulmonary problems. This prophylactic strategy cannot be recommended.
Therapeutic granulocyte transfusions have yielded more encouraging results than have prophylactic transfusions; however, the evidence to date does not support the use of granulocytes in the routine treatment of neutropenic patients. A survival benefit noted in some small studies (1, 38) was not confirmed by a larger, randomized study by Winston et al. (80) . In this large trial, granulocytopenic patients It has been suggested that the therapeutic use of granulocytes might prove more efficacious if larger quantities of cells could be administered (85) . While currently unfeasable, improved techniques in the harvest of granulocytes could someday make this possible. In the meantime, these transfusions should be reserved for patients with reversibly defective granulocyte production who have not responded to appropriate antimicrobial therapy.
The prognosis for patients with sepsis becomes significantly more grave at the onset of septic shock. In our own prospective study (Table 4) , patients with sepsis and without shock had a mortality rate of 13% (13) . The mortality rate was 28% for septic patients with shock at trial entry and 43% for those who developed shock after entry. These values highlight a need for the aggressive treatment of sepsis at the earliest possible time during its course. This has been identified as a means of preventing shock and improving outcome. These efforts should be helped considerably by the therapeutic modalities now being developed.
ADVANCES IN THE MANAGEMENT OF SEPSIS
Immunotherapy for infection was first practiced more than 100 years ago when von Behring used an equine antiserum to treat patients with diphtheria (21) . The early years of this century saw the development of antisera against a number of important bacteria. The antibodies against a particular bacterium recognized and acted against that organism only, however (21) . This line of research was almost entirely discontinued after the introduction of effective antimicrobial agents, but interest in serum therapy reemerged when it was realized that broad-spectrum agents were not having the expected impact on mortality caused by bacterial sepsis.
The promise of immunotherapy in the treatment of sepsis was underscored in 1982, when Ziegler and colleagues published the results of their clinical study on a polyclonal antiserum against gram-negative bacteria (89) . Earlier researchers had determined that, whereas the oligosaccharide side chains of gram-negative bacterial LPS differ widely from strain to strain, the core regions of most strains are quite similar (45) . Thus, it was conjectured, broadly effective immunotherapy for gram-negative sepsis in the form of antibodies raised against LPS might be developed through the use of a bacterial strain with an outer membrane that features no side chains, instead bearing only the conserved core elements in its LPS. The strain selected was the J5 mutant of E. coli O111:B4, whose LPS contains only the core determinants, primarily lipid A.
After encouraging results were obtained in animal experiments, the researchers prepared human J5 antiserum by immunizing healthy donors with a J5 boiled-cell vaccine (91) . Over a period of 7 years, 304 patients with clinical symptoms that suggested gram-negative bacteremia were entered into the trial and randomized to treatment with either 1 U of immune serum or the same quantity of preimmune serum as a control. Of the 212 patients in whom the diagnosis of gram-negative bacteremia was subsequently confirmed, 103 received immune serum and 109 received control serum.
Mortality was significantly lower (22%) in the J5 antiserum group than in the control group (39%). In the subset of patients with profound shock who needed vasopressors for more than 6 h, mortality was 77% in the control group and 44% in the antiserum group. The authors concluded that J5 antiserum reduced mortality from gram-negative sepsis by approximately 50% and that this protection was apparent even in the presence of optimal antimicrobial therapy and medical-surgical management (91) .
These findings led to a prophylactic trial of J5 antibody in which high-risk surgical patients were treated with either immune or preimmune plasma at the time of randomization and every 5 days thereafter until they were no longer considered to be at high risk (5) . Because the previous therapeutic trial involving J5 had not shown a significant decrease in mortality among the patients with abdominal infections, the effect of prophylaxis in this group was of considerable interest. In addition, the study allowed researchers to assess the value of this strategy in patients at substantial risk, such as those with multiple trauma, the elderly, and immunocompromised patients undergoing lung surgery.
A total of 262 evaluable patients were entered into the study and observed daily. Although there was no significant difference in the incidence of infection in the J5 antibody study group (36%) compared with the control group (40%), the antibody clearly reduced the serious consequences of gram-negative infection. Patients in the control group had a risk of developing septic shock that was more than twice that in the antibody group. A twofold decrease in mortality was observed among patients in shock who received J5 plasma. The antibody's efficacy was also demonstrated in patients who underwent abdominal surgery. The study also confirmed the specificity of J5's affinity for lipid A, the injurious portion of the bacterial outer membrane, since neither the direct consequences of gram-positive infection nor the infection rate was altered, while the complications of gramnegative infection, such as the inflammatory response, were affected. This suggests that the J5 antibody bound directly to the lipid A portion of the bacteria (5).
In patients with SIRS, retrospective analysis had demonstrated a significant correlation between the serum titers of antibody to core glycolipid and survival (47) . Nevertheless, VOL. 6, 1993 the relationship between the level of J5 antibody achieved in septic patients and the improvement seen in their outcome remained to be demonstrated (4, 91) . Important follow-up studies indicated that a human IgG antibody to E. coli J5 was not effective in reducing complications of gram-negative sepsis (18) and that the protective activity of the antiserum lay almost entirely in the IgM antibody (46) .
Despite these encouraging results, polyclonal J5 antiserum is not suitable for commercial development for a number of reasons. These include the adverse effects of vaccination on serum donors; the variability of antiserum activity; the need to use pooled human blood, thereby creating a risk for transmission of viral disease; and the difficulty of producing large quantities of antiserum.
Fortunately, the discovery and elaboration of hybridoma technology have allowed the mass production of IgM monoclonal antibodies that may prove to be useful in the management of gram-negative sepsis. Preclinical and clinical studies on both murine and human monoclonal antibodies have been encouraging. A detailed analysis of these monoclonal antibodies follows.
On the basis of the obvious promises held out by antiendotoxin therapy, the anti-endotoxin antibody E5 was developed, using the following procedure (32) . After mice were immunized with boiled E. coli J5 cells, their spleen cells were fused with murine myeloma cells to yield a single (monoclonal) cell line producing an antibody directed specifically against lipid A. Selection of the proper cell line provided a culture that continued to produce an IgM antibody that reacts with the core region of gram-negative bacterial outer membranes (71) . A recent in vitro study that employed boiled bacterial cells and a large panel of LPS and lipid A preparations found that lipid A was the apparent epitope on LPS to which E5 binds (84) .
The results seen in preclinical and clinical trials of E5 have been encouraging. After significantly improved survival was seen in mice challenged with gram-negative organisms and treated with E5 (87), and following human pharmacokinetic studies (74), two major clinical trials of E5 were undertaken. In the first trial, a double-blind comparison of E5 and placebo in patients with suspected gram-negative sepsis showed that mortality among those in the subgroup with documented gram-negative infection was 22% in patients given routine therapy alone but only 7% in patients given routine therapy plus E5 (34) .
In a subsequent large, double-blind trial in which 33 centers participated, 486 patients with suspected gramnegative sepsis were enrolled (35 E5 was not significantly more effective than placebo in improving survival among the 316 patients with documented gram-negative sepsis. In the subgroup (n = 137) of patients with gram-negative sepsis who were not in refractory shock at study entry, however, patients taking E5 had a significantly lower mortality rate (hazard ratio = 2.3; P = 0.01). Both bacteremic and nonbacteremic patients contributed to improved survival in the E5 group as a whole, since they were associated with relative risks of 2.3 and 2.1, respectively. Survival data are summarized in Fig. 3 there is not enough in vitro evidence of HA-1A's ability to effectively bind endotoxin. They quoted in vitro and animal studies of the antibody that bring into doubt its ability to bind to endotoxin and decrease the host's systemic response. They also had familiar critiques on the differences between the control and treatment groups in the clinical studies. These articles were rebutted by a letter from Ziegler and Smith (90) found in the same issue. They think that there has been much in vitro work in the last 6 years showing the specificity and strength of HA-1A binding to endotoxin.
They also pointed out that animal studies cannot be applied to human use of the antibody because of the divergent responses of animals to endotoxin.
To summarize the much discussed results of the trials into E5 and HA-1A use in septic patients, it is easy to criticize any study because of imbalances between the placebo and treatment groups. These will inevitably occur by chance if enough baseline criteria are analyzed. However, in my opinion, these studies of anti-endotoxin antibodies have been rigorously planned and well executed. I believe that, ultimately, both murine and human monoclonal antibodies will be highly useful. If these agents become generally available and commonly used, they should herald a significant advance in the management of gram-negative sepsis. It should also be remembered that imagination is the only limit to the types of new agents that may be used to fight gram-negative sepsis. Currently, several are being developed for use by researchers (11) . While the use of antibodies to endotoxin may be an important adjunct to the treatment of VOL. 6, 1993 ?--l 
